Akero Therapeutics Inc’s filing revealed that its Chief Development Officer Yale Catriona unloaded Company’s shares for reported $0.39 million on May 15 ’25. In the deal valued at $39.30 per share,10,000 shares were sold. As a result of this transaction, Yale Catriona now holds 95,034 shares worth roughly $3.62 million.
Then, CATRIONA YALE bought 30,000 shares, generating $1,136,400 in total proceeds.
Before that, Cheng Andrew sold 30,000 shares. Akero Therapeutics Inc shares valued at $1,244,455 were divested by the President and CEO at a price of $41.48 per share. As a result of the transaction, Cheng Andrew now holds 594,324 shares, worth roughly $22.67 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -1.88% to $38.14. Over the last five days, the stock has lost -8.16%. Akero Therapeutics Inc shares have risen nearly 37.10% since the year began. Nevertheless, the stocks have risen 81.02% over the past one year.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-04-30, growing by 1.3 million shares to a total of 6.78 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 5.49 million shares. There was a rise of 19.11%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
